• Je něco špatně v tomto záznamu ?

Use of mucolytics in COPD: A Delphi consensus study

A. Papi, S. Avdeev, PMA. Calverley, CR. Cordeiro, M. Jesenak, V. Koblížek, D. Petkova, P. Rogliani, H. Tarraf, N. Tzanakis, R. Ulmeanu, E. Uzaslan, Y. Adir

. 2020 ; 175 (-) : 106190. [pub] 20201113

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026401

BACKGROUND: International guidelines recommend mucolytic agents as add-on therapy in selected patients with COPD because they may reduce exacerbations and improve health status. As the evidence varies among mucolytic agents, we used the Delphi method to assess consensus amongst an international panel of COPD experts on mucolytics use in COPD. METHODS: 53 COPD experts from 12 countries were asked to complete an online questionnaire and rate their agreement with 15 statements using a 5-point scale. The mucolytic agents evaluated were carbocysteine, erdosteine and N-acetylcysteine (NAC). Data were collected anonymously and consensus presented using descriptive statistics. RESULTS: The 47 respondents reached consensus on the statements. They agreed that regular treatment with mucolytic agents effectively reduces the frequency of exacerbations, reduces the duration of mild-to-moderate exacerbations, and can increase the time to first exacerbation and symptom-free time in COPD patients. Consensus was consistently highest for erdosteine. The experts agreed that all three mucolytics display antioxidant and anti-inflammatory activity. Erdosteine and NAC were thought to improve the efficacy of some classes of antibacterial drugs. All three mucolytics were considered effective for the short-term treatment of symptoms of acute exacerbations when added to other drugs. The panel agreed that approved doses of mucolytic agents have favorable side-effect profiles and can be recommended for regular use in patients with a bronchitic phenotype. CONCLUSIONS: Consensus findings support the wider use of mucolytic agents as add-on therapy for COPD. However, the differences in pharmacological actions and clinical effectiveness must be considered when deciding which mucolytic to use.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026401
003      
CZ-PrNML
005      
20211026132932.0
007      
ta
008      
211013s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.rmed.2020.106190 $2 doi
035    __
$a (PubMed)33217537
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Papi, Alberto $u Respiratory Medicine, University of Ferrara, Ferrara, Italy. Electronic address: ppa@unife.it
245    10
$a Use of mucolytics in COPD: A Delphi consensus study / $c A. Papi, S. Avdeev, PMA. Calverley, CR. Cordeiro, M. Jesenak, V. Koblížek, D. Petkova, P. Rogliani, H. Tarraf, N. Tzanakis, R. Ulmeanu, E. Uzaslan, Y. Adir
520    9_
$a BACKGROUND: International guidelines recommend mucolytic agents as add-on therapy in selected patients with COPD because they may reduce exacerbations and improve health status. As the evidence varies among mucolytic agents, we used the Delphi method to assess consensus amongst an international panel of COPD experts on mucolytics use in COPD. METHODS: 53 COPD experts from 12 countries were asked to complete an online questionnaire and rate their agreement with 15 statements using a 5-point scale. The mucolytic agents evaluated were carbocysteine, erdosteine and N-acetylcysteine (NAC). Data were collected anonymously and consensus presented using descriptive statistics. RESULTS: The 47 respondents reached consensus on the statements. They agreed that regular treatment with mucolytic agents effectively reduces the frequency of exacerbations, reduces the duration of mild-to-moderate exacerbations, and can increase the time to first exacerbation and symptom-free time in COPD patients. Consensus was consistently highest for erdosteine. The experts agreed that all three mucolytics display antioxidant and anti-inflammatory activity. Erdosteine and NAC were thought to improve the efficacy of some classes of antibacterial drugs. All three mucolytics were considered effective for the short-term treatment of symptoms of acute exacerbations when added to other drugs. The panel agreed that approved doses of mucolytic agents have favorable side-effect profiles and can be recommended for regular use in patients with a bronchitic phenotype. CONCLUSIONS: Consensus findings support the wider use of mucolytic agents as add-on therapy for COPD. However, the differences in pharmacological actions and clinical effectiveness must be considered when deciding which mucolytic to use.
650    _2
$a acetylcystein $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000111
650    _2
$a karbocystein $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D002233
650    12
$a konsensus $7 D032921
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a expektorancia $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D005100
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a zdravotní stav $7 D006304
650    _2
$a lidé $7 D006801
650    _2
$a internacionalita $7 D038622
650    _2
$a mužské pohlaví $7 D008297
650    12
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a chronická obstrukční plicní nemoc $x farmakoterapie $7 D029424
650    _2
$a průzkumy a dotazníky $7 D011795
650    12
$a syndrom vzplanutí nemoci $7 D000067251
650    _2
$a thioglykoláty $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D013864
650    _2
$a thiofeny $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D013876
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Avdeev, Sergey $u Sechenov First Moscow State Medical University, Moscow, Russia
700    1_
$a Calverley, Peter M A $u Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK
700    1_
$a Cordeiro, Carlos R $u Faculty of Medicine, University of Coimbra, Coimbra, Portugal
700    1_
$a Jesenak, Milos $u Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Martin, Slovakia
700    1_
$a Koblížek, Vladimir $u Pneumology Dept., University Hospital Hradec Králové, Faculty of Medicine, Charles University, Hradec Králové, Czech Republic
700    1_
$a Petkova, Diana $u Medical University Varna, Bulgaria; University Hospital St. Marina, Varna, Bulgaria
700    1_
$a Rogliani, Paola $u Respiratory Medicine Unit, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy
700    1_
$a Tarraf, Hesham $u Faculty of Medicine, University Medical School, Cairo, Egypt
700    1_
$a Tzanakis, Nikolaos $u Pulmonology Dept., University Hospital of Crete, Crete, Greece
700    1_
$a Ulmeanu, Ruxandra $u Institute of Pneumology "Marius Nasta", Bucharest, Romania
700    1_
$a Uzaslan, Esra $u Faculty of Medicine, Pulmonology Dept., Uludağ University, Bursa, Turkey
700    1_
$a Adir, Yochai $u Pulmonary Division, Lady Davis-Carmel Medical Center, Haifa, Israel
773    0_
$w MED00004105 $t Respiratory medicine $x 1532-3064 $g Roč. 175, č. - (2020), s. 106190
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33217537 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132938 $b ABA008
999    __
$a ok $b bmc $g 1715193 $s 1146908
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 175 $c - $d 106190 $e 20201113 $i 1532-3064 $m Respiratory medicine $n Respir Med $x MED00004105
LZP    __
$a Pubmed-20211013
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace